AUS
NZ
UK
CA
USA
IND
Highlights:
TG Therapeutics secures top spot on Deloitte’s Technology Fast 500 list as the fastest-growing biotech company in North America.
Revenue growth driven by the success of BRIUMVI®, its treatment for relapsing multiple sclerosis, with a 230% increase in Q3 2024.
The company raises its full-year revenue guidance, highlighting its strong market position and pipeline expansion.
TG Therapeutics (NASDAQ:TGTX) has been making significant strides in the biotech industry, particularly with its breakthrough treatment, BRIUMVI®, for relapsing multiple sclerosis. Recognized as the fastest-growing company in North America on Deloitte's Technology Fast 500 list, TG Therapeutics has demonstrated exceptional performance, driven by the strong market reception of BRIUMVI®, approved in late 2022.
In Q3 2024, the company reported an impressive 230% year-over-year revenue growth, primarily fueled by BRIUMVI®'s success. U.S. revenue from the treatment reached $83.3 million, marking a 15% increase from the previous quarter. As a result, TG Therapeutics has raised its full-year revenue guidance to a range of $300–305 million, underlining its growing presence in the multiple sclerosis treatment market.
BRIUMVI® has proven to be a game-changer, with over 92% of patients showing no disability progression after five years of treatment. This clinical success positions BRIUMVI® to redefine therapeutic standards in multiple sclerosis treatment. In addition, the company is expanding its pipeline with a subcutaneous version of BRIUMVI® and innovative CAR-T cell therapies aimed at addressing other autoimmune diseases.
TG Therapeutics’ solid financial position, with $341 million in cash, positions the company for sustained growth in the years ahead. Strategic collaborations, including with FUJIFILM Diosynth Biotechnologies, further enhance its ability to deliver on its commitments to the autoimmune therapy market. As TG Therapeutics continues to progress with its pipeline, its focus on advancing treatment options ensures that it remains a prominent player in the biotechnology field.
